腹腔镜术联合醋酸曲普瑞林治疗子宫内膜异位症的87例临床效果观察

目的:探讨腹腔镜术联合醋酸曲普瑞林治疗子宫内膜异位症临床效果,以期提高临床诊治水平。方法:选取2010年5月至2013年5月87例子宫内膜异位症患者为研究对象,分成两组,对照组43例,予腹腔镜术治疗,观察组44例,加用醋酸曲普瑞林治疗,观察两组治疗后疗效指标变化情况。结果:疗效上,对照组缓解率30.23%,总有效率76.74%;观察组缓解率45.45%,总有效率93.18%,两组比较差异有统计学意义(P<0.05)。两组治疗前在盆腔痛、痛经和性交痛积分和CA-125、FSH、E2水平比较差异无统计学意义(P>0.05),治疗后和治疗前比较差异有统计学意义(P<0.05),治疗后较治疗前比较差异更有统计学意义(P<0.05)。结论:腹腔镜术联合醋酸曲普瑞林治疗子宫内膜异位症临床效果显著。     

曲普瑞林联合达那唑预防子宫内膜异位症术后复发的效果分析

目的:探讨曲普瑞林联合达那唑预防子宫内膜异位症术后复发的效果。方法:选取80例行腹腔镜手术治疗的子宫内膜异位症患者,将其随机分为观察组与对照组,每组40例患者。观察组患者术后予以曲普瑞林和达那唑治疗预防复发,对照组患者术后予以达那唑治疗预防复发。比较两组患者的治疗效果和不良反应发生情况。结果:两组患者治疗前FSH、E2水平和痛经评分比较,其差异均无统计学意义(均P> 0. 05),两组患者治疗后FSH、E2水平和痛经评分均比治疗前下降(P <0. 05或P <0. 01),观察组患者下降幅度明显大于对照组患者(P <0. 05);观察组患者治疗后临床总有效率明显优于对照组患者(P <0. 05);两组患者治疗后不良反应发生率比较,差异无统计学意义(P> 0. 05)。结论:采用曲普瑞林联合达那唑预防子宫内膜异位症术后复发效果显著,能够明显改善患者临床症状、减少不良反应,是一种安全有效的治疗方案。     

曼月乐治疗子宫内膜异位症疗效分析

目的:研究分析曼月乐对子宫内膜异位症患者的临床治疗效果。方法:选取我院2013年5月至2015年5月收治的74例采用曼月乐进行子宫内膜异位症治疗的患者为研究对象,比较治疗各阶段月经量、痛经程度、CA125值变化情况。结果:放置曼月乐环后,随着治疗时间的增加,患者VAS疼痛评分明显降低,月经量明显减少,CA125值明显降低,关键指标治疗前后比较差异均具有统计学意义(P0.05)。治疗总有效率达到95.94%。结论:采用曼月乐治疗子宫内膜异位症疗效显著,安全可靠,对于无生育要求妇女可进行临床应用推广。     

宫瘤消胶囊联合达那唑胶囊治疗子宫内膜异位症的临床效果及安全性研究

目的探讨宫瘤消胶囊联合达那唑胶囊治疗子宫内膜异位症,对患者激素水平、治疗效果、以及远期安全性的影响。方法选取2015年12月至2017年12月深圳市龙华区人民医院诊治的130例子宫内膜异位症患者作为研究对象。依据随机数字表法分为对照组和观察组,每组各65例患者。对照组行达那唑治疗方案,观察组行达那唑、宫瘤消联合治疗方案。比较治疗前后激素水平变化、治疗前后疼痛情况及对日常生活工作影响情况、治疗效果以及治疗后随访情况。结果治疗前两组患者激素水平无统计学意义(P>0.05),具有可比性。治疗前后两组患者FSH、LH无显著变化,差异无统计学意义(P>0.05)。治疗后两组患者E2、PRL、P较治疗前有改善,差异具有统计学意义(P<0.05)。治疗后观察组患者E2、PRL、P优于对照组,差异具有统计学意义(P<0.05)。治疗前两组患者VAS评分及kupperman评分差异无统计学意义(P>0.05)。治疗后两组患者VAS评分及kupperman评分较治疗前有改善,差异具有统计学意义(P<0.05)。治疗后观察组患者VAS评分及kupperman评分优于对照组,差异具有统计学意义(P<0.05)。两组患者治疗总有效率分别为92.30%和78.46%,观察组优于对照组,差异具有统计学意义(P<0.05)。两组患者不良反应发生率及1年妊娠率差异无统计学意义(P>0.05)。观察组患者1年复发率低于对照组,差异具有统计学意义(P<0.05)。结论子宫内膜异位症患者行宫瘤消胶囊联合达那唑胶囊治疗,能够有效改善患者激素水平及疼痛情况,提高治疗效果及降低复发率,安全性高,具有进一步探讨的临床意义。     

醋酸亮丙瑞林微球治疗子宫内膜异位症效果研究

目的:观察醋酸亮丙瑞林微球治疗子宫内膜异位症的效果及对患者CA125水平的影响,旨在为子宫内膜异位症患者术后选择巩固药物治疗提供科学依据。方法:选取子宫内膜异位症患者86例作为研究对象。均经腹腔镜术后病理组织学确诊,随机分为实验组和对照组,每组各43例。实验组给予醋酸亮丙瑞林微球治疗。对照组给予口服避孕药达英-35治疗。观察并比较两组患者的疗效及药物不良反应的发生情况,测定患者外周血CA125水平。结果:两组患者的总有效率无统计学差异(P0.05)。停药后6个月,实验组无复发,对照组出现4例复发,复发率有统计学差异(P0.05)。治疗前,两组患者的CA125水平无统计学差异,治疗后,两组患者的CA125均较治疗前降低,差异有统计学意义(P0.05)。治疗前,实验组与对照组患者性激素水平无统计学差异(P0.05),治疗后,实验组与对照组患者性激素水平均较治疗前降低,且实验组水平均低于对照组,差异有统计学意义(P0.01)。两组之间的不良反应发生率无统计学差异(P0.05)。结论:醋酸亮丙瑞林微球治疗子宫内膜异位症的疗效确切,复发率低,可降低血清CA125水平以阻滞疾病进展,虽有部分不良反应,但多为低雌激素症状,且程度较轻,可进一步临床推广。     

左炔诺孕酮宫内节育系统联合宫腔镜子宫内膜切除术治疗围绝经期异常子宫出血的临床疗效

目的探讨左炔诺孕酮宫内节育系统联合宫腔镜子宫内膜切除术治疗围绝经期异常子宫出血的临床疗效。方法选取2017年1月至2018年6月东阳市中医院诊治的围绝经期异常子宫出血患者146例作为研究对象。随机分为观察组和对照组,各73例;两组患者均采取左炔诺孕酮宫内节育系统治疗,观察组联合宫腔镜子宫内膜切除术。随访12个月,比较两组患者不同时间点的月经失血图(PBAC)评分、子宫内膜厚度、子宫体积,以及血红蛋白、血清糖类抗原125(CA125)水平,比较有效率,观察复发率和不良反应发生情况。结果两组患者在治疗前PBAC评分上差异无统计学意义(P0.05);观察组治疗后1个月、3个月、6个月、12个月PBAC评分均较治疗前明显降低,与对照组比较,差异均具有统计学意义(P0.05)。两组患者在治疗前子宫内膜厚度、子宫体积上差异均无统计学意义(P0.05);观察组治疗后6个月、12个月的子宫内膜厚度、子宫体积均较治疗前明显减小,与对照组比较,差异均具有统计学意义(P0.05)。两组患者在治疗前血红蛋白、CA125水平上差异无统计学意义(P0.05);观察组治疗后6个月、12个月的血红蛋白均较治疗前明显升高,CA125水平均较治疗前明显降低,与对照组比较,差异均具有统计学意义(P0.05)。观察组治疗后1个月、3个月、6个月、12个月的有效率均明显高于对照组,差异均具有统计学意义(P0.05);观察组复发率和不良反应发生率均明显低于对照组,差异均具有统计学意义(P0.05)。结论左炔诺孕酮宫内节育系统联合宫腔镜子宫内膜切除术治疗围绝经期异常子宫出血患者,其临床疗效确切、安全可靠,在控制病情、减少复发和不良反应发生方面均具有优势,值得临床推广应用。     

枸橼酸氯米芬联合来曲唑对排卵障碍不孕症患者卵泡成熟时间、生殖激素水平的影响

目的研究枸橼酸氯米芬联合来曲唑对排卵障碍不孕症患者卵泡成熟时间、生殖激素水平的影响。方法选取2018年7月至2019年7月衡水市第二人民医院诊治的146例排卵障碍不孕症患者作为研究对象。按照完全随机法分为联合治疗组(n=73)和来曲唑治疗组(n=73)。对来曲唑治疗组患者使用来曲唑进行治疗,对联合治疗组使用枸橼酸氯米芬联合来曲唑进行治疗。对两组患者雌二醇(E_2)、孕酮(P)、子宫膜厚度、卵泡成熟时间、脂肪因子[内脂素(VF)、脂联素(APN)及瘦素(LP)]水平进行检测并作出比较;统计患者不良反应发生率、排卵率以及妊娠率。结果治疗后联合治疗组患者生殖激素E_2、P水平高于来曲唑治疗组患者,差异具有统计学意义(P0.05);治疗后联合治疗组患者子宫内膜厚度高于来曲唑治疗组患者,差异具有统计学意义(P0.05),联合治疗组患者卵泡成熟时间低于来曲唑治疗组患者,差异具有统计学意义(P0.05);治疗后联合治疗组患者不良发生率高于来曲唑治疗组患者,差异具有统计学意义(P0.05);治疗后联合治疗组患者脂肪因子VF、LP低于来曲唑治疗组患者,差异具有统计学意义(P0.05),联合治疗组患者脂肪因子APN高于来曲唑治疗组患者,差异具有统计学意义(P0.05);治疗后联合治疗组患者排卵率、妊娠率均高于来曲唑治疗组患者,差异均具有统计学意义(均P0.05)。结论枸橼酸氯米芬联合来曲唑治疗排卵障碍不孕症患者可以提高生殖激素E_2、P水平,降低卵泡成熟时间,增加子宫膜厚度,提高排卵率和妊娠率。     

左炔诺孕酮宫内缓释系统治疗子宫腺肌症的疗效及安全性观察

目的:探讨左炔诺孕酮宫内缓释系统(LNG-IUS)治疗子宫腺肌症的疗效及安全性。方法:选择82例子宫腺肌症患者,所有患者均在宫内放置LNG-IUS,观察患者治疗前、治疗后1月、治疗后6月月经量评分、痛经评分、子宫内膜厚度、子宫体积、血清性激素水平及不良反应发生情况。结果:治疗后1个月患者月经量评分、痛经评分、子宫体积和子宫内膜厚度较治疗前改善,治疗6个月后患者月经量评分、痛经评分、子宫体积和子宫内膜厚度较治疗前明显改善。治疗后6个月患者血清性激素水平与治疗前比较无明显差异。治疗后6个月所有82例患者中21例出现不良反应,不良反应发生率为25.6%。结论:LNG-IUS治疗子宫腺肌症具有疗效显著、操作简便、对性激素水平影响少和不良反应少等优点。     

3种不同剂量来曲唑分别联合枸橼酸氯米芬对PCOS不孕患者性激素和内膜的影响

目的探讨3种剂量来曲唑分别联合枸橼酸氯米芬对多囊卵巢综合征(polycystic ovary syndrome,PCOS)不孕患者性激素和内膜的影响。方法选取2015年1月至2017年12月成都市送子鸟不孕不育医院诊治的129例PCOS不孕患者作为研究对象。按照随机数表法将其平均分为A组、B组和C组,每组43例患者,选择同期月经正常的40例育龄妇女为参照组。A、B和C组患者在月经周期均给予来曲唑联合枸橼酸氯米芬治疗,其中A组患者来曲唑剂量为2.5mg/d,B组患者来曲唑剂量为5mg/d,C组患者来曲唑剂量为7.5mg/d,三组患者最大卵泡直径不小于20mm时通过人绒毛膜促性腺激素(hCG)进行诱发排卵。比较四组成员hCG期间相关激素和血清性激素结合球蛋白(SHBG)水平、子宫内膜厚度及分型、排卵和妊娠情况。结果 A组、B组和C组患者的卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E_2)和SHBG水平均明显低于参照组成员,睾酮(T)水平均明显高于参照组成员(均P0.05);A组和B组患者的FSH、LH、E_2和SHBG水平均明显低于C组患者,T水平均明显高于C组患者,其差异均具有统计学意义(均P0.05);A组患者的FSH、LH、E_2和SHBG水平均明显低于B组患者,T水平均明显高于B组患者,其差异均具有统计学意义(均P0.05)。在优势卵泡发育至10mm～12mm、14mm～16mm和18mm～20mm时间节点时:A组、B组和C组患者的雌激素水平和子宫内膜厚度均明显低于参照组成员(均P0.05);C组患者的雌激素水平和子宫内膜厚度均明显低于A组和B组患者,其差异均具有统计学意义(均P0.05);B组患者的雌激素水平和子宫内膜厚度均明显低于A组患者,其差异军具有统计学意义(均P0.05)。四组成员hCG日均未见C型子宫内膜,且四组成员A型、B型占比比较,其差异均无统计学意义(均P0.05)。四组成员排卵率相比,其无差异均无统计学意义(均P0.05);A组、B组和C组患者的妊娠率均明显低于参照组成员,且A组和B组患者的妊娠率低于C组患者,A组患者的妊娠率低于B组患者,其差异均具有统计学意义(均P0.05)。结论来曲唑联合枸橼酸氯米芬可以促进PCOS不孕患者性激素和SHBG的分泌,对雌激素和子宫内膜有一定的抑制作用,但达到胚胎着床的要求,能够提高患者的妊娠率,以7.5mg/d来曲唑剂量的作用效果最为明显。     

活血化瘀补肾中药治疗联合腹腔镜手术治疗子宫内膜异位症不孕患者临床研究

目的:探讨研究活血化瘀补肾中药治疗联合腹腔镜手术治疗子宫内膜异位症不孕患者的临床效果。方法:病例来源于我院2010年5月至2014年1月收治的符合诊断标准的126例子宫内膜异位症不孕患者,依据随机数字表法将所有患者均分成观察组和对照组,每组各63例。对照组施行腹腔镜手术结合常规的西医治疗,观察组给予活血化瘀补肾中药联合腹腔镜手术治疗。比较两组病患妊娠情况、中医证候积分等指标。结果:观察组治疗后CA-125、LH、FSH、E2等指标值均明显优于对照组,比较差异显著(P0.01);观察组治疗后中医症候积分与痛经积分均显著优于对照组,比较差异存在统计学意义(P0.05);观察组治疗后一年痛经与子宫内膜异位症复发情况均明显优于对照组,比较差异存在统计学意义(P0.01);观察组总的怀孕率显著优于对照组,比较差异存在统计学意义(P0.01)。结论:活血化瘀补肾中药结合腹腔镜手术能够有效提升子宫内膜异位症不孕病患怀孕率,显著降低疾病的复发,值得在临床上推广使用。     

女性闭经患者血清FSH、LH、PRL水平测定分析

目的:通过检测闭经女性患者血清中卵泡刺激素(FSH)、黄体生成素(LH)、催乳素(PRL)的水平,探讨其在闭经女性患者中的意义。方法:选取本院妇科门诊就诊的52例闭经患者为观察组,选取本院健康体检中心月经正常的52例女性为对照组。选取对象的时间均来自2012年4月至2015年4月在本院进行性激素检查的女性。采用化学发光免疫法分别检查两组女性血清中FSH、LH、PRL、雌二醇(E_2)、孕酮(P)的水平,以进行对照研究。结果:观察组患者血清中FSH、LH、PRL的值分别为(14.68±13.26)m U/mL、(12.321±10.14)m U/mL、(38.85±33.14)ng/mL明显高于对照组血清中的水平,具有明显的统计学(P0.01),观察组E_2的水平为(40.98±15.48)pg/mL明显低于对照组(51.54±8.87)pg/mL(P0.05),对照组和观察组孕酮(P)的值分别为(8.55±0.30)ng/mL和(0.56±0.26)ng/mL有明显差异,具有统计学意义(P0.05)。闭经时间6个月患者血清中PRL(18.67±6.87)mu/mL、FSH(19.23±5.14)mu/mL、LH(45.85±3.124)ng/mL的水平明显高于闭经时间6个月激素水平(P0.049)。但闭经时间6个月患者血清中P(8.37±12.26)ng/mL、E_2(0.42±0.53)ng/mL水平则低于闭经时间6个月的患者血清内其激素的水平(P0.044)。结论:通过对闭经女性患者性激素水平的检测,可以根据血清中性激素水平的高低进行病因诊断和基本的对症治疗。     

Early serial Q-switched ruby laser therapy for medium-sized to giant congenital melanocytic naevi

Background  The sebaceous gland exhibits an independent peripheral endocrine function and expresses receptors for neuropeptides. Previous reports have confirmed the presence of a complete corticotropin-releasing hormone (CRH) system in human sebocytes in vitro . The capability of hypothalamic CRH to induce lipid synthesis, induce steroidogenesis and interact with testosterone and growth hormone implicates a possibility of its involvement in the clinical development of acne.
Objectives  The purpose of the study was to detect expression changes of CRH/CRH binding protein (CRHBP)/CRH receptors (CRHRs) in acne-involved skin, especially in the sebaceous glands.
Methods  Expression of CRH/CRHBP/CRHRs was analysed by immunohistochemistry in biopsies from facial skin of 33 patients with acne, noninvolved thigh skin of the same patients and normal skin of eight age-matched healthy volunteers.
Results  Very strong positive reaction for CRH was observed in acne-involved skin in all types of sebaceous gland cells, irrespective of their differentiation stage, whereas in noninvolved and normal skin sebaceous glands exhibited a weaker CRH staining depending upon the differentiation stage of sebocytes. The strongest reaction for CRHBP in acne-involved sebaceous glands was in differentiating sebocytes. CRHR-1 and CRHR-2 exhibited the strongest expression in sweat glands and sebaceous glands, respectively.
Conclusions  Expression of the complete CRH system is abundant in acne-involved skin, especially in the sebaceous glands, possibly activating pathways which affect immune and inflammatory processes leading to the development and stress-induced exacerbation of acne.     

Immunoreactivity of corticotropin-releasing hormone, adrenocorticotropic hormone and alpha-melanocyte-stimulating hormone in alopecia areata

Psychological factors are believed to play a role in the pathogenesis of alopecia areata (AA), a frequently encountered hair disorder. In our study, statistically significant elevation of psychological stress was felt by AA patients prior hair loss compared with control, which was strongly believed contributory to hair loss (t-test, P < 0.01). The corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) mRNA have been identified in the basal layer of the epidermis and pilosebaceous units of the normal scalp. And with the recent discovery of melanocytes and dermal fibroblasts capable of corticosterone production, the presence of a local stress response system resembling the hypothalamic-pituitary-adrenal (HPA) axis has been suggested. The local stress response system is involved in regulation of the normal hair cycle, but its precise role in AA is unknown. The influence of a local HPA axis or rather, CRH-POMC axis in AA was investigated by analysing immunohistochemically the expression levels of CRH and POMC peptides, including the adrenocorticotropic hormone (ACTH) and alpha-melanocyte-stimulating hormone (alpha-MSH), in a number of AA lesions and normal scalp (as control). The epidermis and pilosebaceous units of normal scalp stained weakly with CRH, ACTH and alpha-MSH, whereas those from the affected sites of the AA group showed intense expression of the peptides (chi-square test, P < 0.01). The meaning of this enhanced expression and their role in the pathogenesis of AA should be further evaluated in future.     

Investigation of the corticotropin-releasing hormone-proopiomelanocortin axis in various skin tumours

BACKGROUND: Various types of external stress cause the skin and central neuroendocrine system to express corticotropin-releasing hormone (CRH)-proopiomelanocortin (POMC) axis-related hormones. However, the precise role of the CRH-POMC axis-related hormones in various skin tumours is unclear. OBJECTIVES: This study examined expression patterns of the CRH-POMC axis-related hormones in skin tumours. METHODS: The production of CRH, adrenocorticotropic hormone (ACTH) and alpha-melanocyte-stimulating hormone (alpha-MSH) in various tumour cell lines including HaCaT and primary keratinocytes was examined using an enzyme-linked immunosorbent assay. Immunohistochemical analysis of the skin tumours was also performed. RESULTS: CRH, ACTH and alpha-MSH were strongly expressed in malignant skin tumour cell lines such as G-361 and DX-3 (both malignant melanoma, MM). However, normal and haematological malignancy cell lines did not express the CRH-POMC axis-related hormones. Immunohistochemical analysis of the skin tumours showed that MM (80%), squamous cell carcinoma (SCC, 70%) and basal cell carcinoma (BCC, 10%) had strong immunoreactivity (++/+++) for CRH. Strong ACTH and alpha-MSH expression was observed in MM (70% and 50%, respectively), SCC (80% and 60%, respectively) and BCC (70% and 50%, respectively). CONCLUSIONS: We report that an increase in the level of the CRH-POMC axis-related hormones is associated with malignant skin tumours such as MM. These results highlight the importance of the CRH-POMC axis-related hormones in the malignant tendency of skin tumours.     

青春期延迟56例临床分析

目的:探讨青春期延迟的分型诊断和治疗方法。方法:采用化学发光法测定促卵泡刺激素(FSH)、黄体生成素(LH)、睾酮(T)、雌二醇(E2)、泌乳素(PRL),同时进行绒毛膜促性腺素(HCG)兴奋试验。并进行外周血染色体检查和B超检查睾丸、附睾、精索、前列腺、精囊腺。根据检查结果进行分型诊断和病因学诊断,治疗以缺什么补什么为原则。结果:本组病例共56例,其中高促性腺激素型6例(占10.71%),低促性腺激素型50例(占89.29%)。通过激素的补充治疗,第二性征和阴茎均能得到改善,但睾丸生长缓慢,低促性腺激素型部分患者能恢复生殖功能,本组病例中3例精子密度正常,其中1例妻子已怀孕。结论:青春期延迟通过分型诊断,并进行相应的内分泌补充治疗,第二性征和阴茎发育正常,低促性腺激素型患者尚能恢复生殖功能。     

女性黄褐斑患者血清性激素水平的研究

目的:了解黄褐斑发病与女性血清性激素水平的关系。方法:采用放射免疫法检测血清性激素六项。结果:45例女性黄褐斑患者与30例正常对照组血清性激素六项比较无显著性差异(P>0.05)。结论:未发现性激素水平与黄褐斑之间存在密切的关系。     

女性SLE患者血清性激素水平研究

为了探讨性激素在ＳＬＥ发病中的作用,我们采用放射免疫法检测了２０例女性ＳＬＥ患者血清睾酮（Ｔ）、游离睾酮（ＦＴ）、二氢睾酮（ＤＨＴ）、脱氢表雄酮（ＤＨＥＡ）、雌二醇（Ｅ２）、孕酮（Ｐｒ）和泌乳素（ＰＲＬ）水平。结果发现患者血清Ｔ、ＦＴ、ＤＨＴ、ＤＨＥＡ、Ｐｒ明显低于正常对照,ＰＲＬ明显高于正常对照（Ｐ〈０．０５）,Ｅ２无显著差异（Ｐ〉０．０５）;未使用皮质类固醇治疗的患者血清雄激素水平也显著降低（     

Growth hormone levels in psoriasis

Summary Plasma growth-hormone levels in 12 fasting psoriatics were 4.4±1.4 mU/l (mean±SEM), compared to 2.7±1.7 in 5 patients with eczema and 1.2±0.3 in 6 normal subjects. The differences in mean values were not statistically significant and were due to exceptionally high levels of growth hormone in five patients with psoriasis and one patient with eczema. In the psoriatic group the exceptional patients were not distinguished by age or the area of involved skin but they tended to be leaner than those with low plasma-growth hormone levels. We conclude that raised plasma growth hormone cannot be the cause of psoriasis but might be a secondary effect of the skin disease in some patients.     

男性不育症患者抗米勒管激素水平与性激素、精液参数水平的相关性分析

目的 分析男性不育症患者血清及精浆抗米勒管激素(AMH)水平与性激素及精液参数水平的相关性,评估AMH对男性不育症的诊断价值.方法 选取2017年3月至2019年3月烟台市烟台山医院生殖中心诊治的132例男性不育症患者作为研究对象.阴囊彩超下计算双侧睾丸体积,进行精液参数、精浆和血清AMH水平及性激素水平检测.结果 血...     

Parathyroid hormone‐related peptide and the hair cycle – is it the agonists or the antagonists that cause hair growth?

While the effects of PTHrP have been studied for almost 20 years, most of these studies have focused on effects on the termination of the anagen phase, giving an incomplete picture of the overall effect of PTHrP on the hair cycle. PTHrP was determined in several experimental models to promote transition of hair follicles from anagen to catagen phase, which by itself would suggest that PTHrP blockade might prolong the anagen phase and promote hair growth. However, clinical trials with topically applied PTHrP antagonists have been disappointing, leading to a reconsideration of this model. Additional studies performed in mouse models where hair follicles are damaged (alopecia areata, chemotherapy‐induced alopecia) suggest that PTHrP has effects early in the hair cycle as well, promoting hair follicles’ entry into anagen phase and initiates the hair cycle. While the mechanism of this has yet to be elucidated, it may involve activation of the Wnt pathway. Thus, the overall effect of PTHrP is to stimulate and accelerate the hair cycle, and in the more clinically relevant models of hair loss where hair follicles have been damaged or become quiescent, it is the agonists, not the antagonists, which would be expected to promote hair growth.